Search trials – HealthDB

Активни:

Намерени 3,079 изпитвания Стр. 5 от 154

Recruiting Phase 3

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Rett Syndrome

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome

Начало: 30.09.2026 Край: 30.12.2027 Възраст: 5–20 г. Treatment

Australia, United States Biomed Industries, Inc. NCT06840496

Recruiting

Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease

Radiculopathy, Cervical Myelopathy Cervical Neurological Abnormality Disc Disease +1

The goal of this pilot clinical trial is to test the safety and preliminary performance of the ZetaFuse Bone Graft in patient requiring fusion of the C3-C7 vertebral bones due to pain or loss of neurological function. Participants will be treated with ZetaFuse during surgical intervention to reduce pain and the loss of neurological function.

Начало: 01.09.2026 Край: 01.09.2027 Възраст: 22–75 г. Device feasibility

Australia Zetagen Therapeutics, Inc NCT05971329

Recruiting Phase 1/2

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Advanced Renal Cell Carcinoma (RCC)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)

Начало: 30.04.2026 Край: 26.11.2031 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +17 Bristol-Myers Squibb NCT07293351

Recruiting Phase 1

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Начало: 27.04.2026 Край: 24.05.2030 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +6 Incyte Corporation NCT07441694

Recruiting Phase 2

MINImising Total Radiation EXposure in Preterm Infants

Neonatal Respiratory Distress Syndrome PreTerm Neonate

Being born too early (preterm birth) is the leading cause of death in children world-wide. In Australia, 97% of very preterm babies who are admitted to Neonatal Intensive Care Units need breathing support after birth to survive. Despite this significant global impact, neonatal clinicians have few tools available to guide breathing support. Currently, the only lung imaging tool that is routinely used in the Neonatal Intensive Care Unit is a chest X-ray. To reduce radiation exposure, chest X-rays are usually only performed one or two times a day. As chronic lung disease in babies who survive preterm birth is increasing, there is an urgent need to develop new ways to monitor the lungs of these fragile babies. Lung ultrasound is a form of imaging that is fast, gentle and radiation free. However, it has not been routinely adopted into caring for preterm babies in most countries. This is because there are no randomised controlled trials that have demonstrated the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. The investigators will conduct a randomised controlled trial to demonstrate that lung ultrasound is a quick, safe and accurate alternative to chest x-rays in preterm babies.

Начало: 13.04.2026 Край: 01.12.2029 Възраст: до 24 г. Diagnostic

Australia Western Health, Australia NCT06975189

Recruiting Phase 3

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Solid Tumors

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Начало: 09.04.2026 Край: 19.03.2029 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +14 Incyte Corporation NCT07522073

Recruiting Phase 1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Ewing Sarcoma

The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

Начало: 08.04.2026 Край: 26.05.2030 Възраст: от 2 г. Basic science

Australia, United States Amgen NCT07297979

Recruiting

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

Atrial Fibrillation (AF) Persistent Atrial Fibrillation Paroxysmal Atrial Fibrillation (PAF)

Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.

Начало: 08.04.2026 Край: 29.03.2028 Възраст: от 18 г. Treatment

Australia, Belgium, Czechia +3 Medtronic Cardiac Ablation Solutions NCT07298473

Recruiting Phase 4

PeRiOperative Medicine Platform Trial

Surgical Site Infection After Major Surgery Anaesthesia Major Complications Quality of Recovery (QoR-15) +1

Our specific aims are to investigate whether conservative (≤30%), intermediate (50%), or liberal (80%) inspired oxygen during and immediately after surgery: Aim 1: Reduces surgical site infections (SSIs or "wound infections") and other healthcare-associated infections (pneumonia and sepsis). Aim 2: Reduces a pooled composite of serious postoperative complications, leading to a faster and more complete recovery after surgery, and thus increases "days alive and at home up to 30 days after surgery" (DAH30). Primary hypothesis: Liberal (80%) oxygen concentration delivered with anesthesia in patients undergoing major surgery reduces the incidence of SSIs after surgery compared to conservative (≤30%) or intermediate (50%) oxygen concentration. Secondary hypothesis: Hyperoxia (50-80%) delivered with anesthesia in patients undergoing major surgery increases the incidence of pulmonary and other complications after surgery compared to conservative (≤30%) oxygen concentration, resulting in fewer Days At Home (DAH). PROMPT enrolls patients undergoing elective or semi-elective surgery.

Начало: 06.04.2026 Край: 01.12.2035 Възраст: от 18 г. Treatment

Australia, New Zealand Monash University NCT07186634

Recruiting Phase 1

A Phase 1 Study of PVT401 in Healthy Subjects

Inflammatory Bowel Disease (IBD)

The goal of this clinical trial is to learn what happens to PVT401 when it enters the human body and how it affects the immune system. It will also provide information about the safety of PVT401 after a single dose and after multiple doses. The main questions it aims to answer are: Will participants experience any side effects when taking PVT401? How long does it take PVT401 to leave the body after it is administered? Healthy volunteers will participate in either the single ascending dose (SAD) or multiple ascending dose (MAD) phase. In the SAD phase, participants will: stay in the clinic for two nights, get one dose of PVT401 or a placebo intravenously (through a vein) on Day 1, have blood drawn periodically throughout their stay and be monitored for side effects, and return to the clinic for 3 follow up visits over the four weeks after dosing. In the MAD phase, participants will: stay in the clinic for one night prior to each dose of PVT401 or placebo, and get dosed twice a week for 5 weeks. They will have blood drawn periodically throughout the treatment period and be monitored for side effects, and return to the clinic for 4 follow up visits over the six months after dosing.

Начало: 01.04.2026 Край: 01.11.2027 Възраст: 18–65 г. Treatment

Australia Parvus Therapeutics, Inc. NCT07423000

Recruiting Phase 1

A Safety and Pharmacokinetics Study of TL-001 in Healthy Adults and Open-label Assessments in Participants With Ulcerative Colitis

Healthy Volunteer

The goal of this study is to evaluate safety, tolerability, pharmacokinetics (PK)), pharmacodynamics (PD) and immunogenicity of single and multiple ascending dose of TL-003 in healthy adult participants.

Начало: 01.04.2026 Край: 01.04.2027 Възраст: 18–55 г. Treatment

Australia TrueLab Biopharmaceutical Co., Ltd NCT07526519

Recruiting Phase 3

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Myelodysplastic Syndrome Anemia

The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alfa. The study also aims to find out the extent of the immune response to elritercept. The study will also check on the medical problems (safety) of elritercept.

Начало: 01.04.2026 Край: 01.10.2033 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +25 Takeda NCT07422480

Recruiting Phase 1

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Solid Tumours

The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).

Начало: 31.03.2026 Край: 30.08.2027 Възраст: от 18 г. Treatment

Australia, Georgia, Poland +2 AstraZeneca NCT07391670

Recruiting Phase 1

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Healthy Volunteers

The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy participants.

Начало: 31.03.2026 Край: 12.06.2026 Възраст: 18–55 г. Other

Australia Otsuka Pharmaceutical Development & Commercialization, NCT07446400

Recruiting Phase 1/2

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Advanced Solid Tumor Cancer

This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.

Начало: 30.03.2026 Край: 01.10.2030 Възраст: от 18 г. Treatment

Australia, China, Taiwan BioNTech SE NCT07455734

Recruiting Phase 4

A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising

Exercise

The goal of this study is to evaluate the influence of consuming a drink containing a combination of caffeine and green tea extracts on fat oxidation responses at rest, during and after a period of endurance type exercise.

Начало: 26.03.2026 Край: 01.12.2026 Възраст: 18–45 г. Treatment

Australia RDC Clinical Pty Ltd NCT07434752

Recruiting Phase 1/2

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)

This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone. The study is looking at: * What side effects may happen from taking REGN17372 with linvoseltamab * How well REGN17372 and linvoseltamab, or linvoseltamab alone, work in treating multiple myeloma * What is the best dose of REGN17372 when given with linvoseltamab * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects) * If and how REGN17372 and linvoseltamab affect the overall quality of life, daily activities, symptoms and treatment side effects based on participant own feedback (Phase 2)

Начало: 26.03.2026 Край: 30.09.2033 Възраст: от 18 г. Treatment

Australia Regeneron Pharmaceuticals NCT07455851

Recruiting Phase 3

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

ccRCC Renal Cell Carcinoma (Kidney Cancer) Renal Cell Carcinoma (RCC) Renal Cell Cancer Metastatic +2

Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.

Начало: 25.03.2026 Край: 28.02.2029 Възраст: от 18 г. Treatment

Australia Telix Pharmaceuticals (Innovations) Pty Limited NCT07197580

Recruiting Phase 1

Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers

Healthy Volunteer

This is a Phase 1b, randomized, double-blind, placebo-controlled, dose escalation study of TRX-100 tablets evaluating the safety, pharmacokinetics, and food effect of single ascending doses of TRX-100 in healthy volunteers.

Начало: 25.03.2026 Край: 01.02.2027 Възраст: 18–65 г. Treatment

Australia Traws Pharma, Inc. NCT07526506

Recruiting Phase 2

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Proteinuric Kidney Diseases

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and treatment-resistant primary membranous nephropathy (TR-pMN). Adolescents with treatment-resistant primary MCD can also participate in this study. The purpose of this study is to find out whether a medicine called BI 764198 helps people with these kidney conditions. Participants are put into 2 groups randomly, which means by chance. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for 20 weeks. All participants also continue their standard medication for their kidney condition during the study. Participants have twice the chance of being placed in the BI 764198 group than in the placebo group. Participants are in the study for about 7 months. During this time, they visit the study site 6 times and have 3 phone calls. Doctors regularly test the protein levels in participants' urine by collecting urine samples. They also check kidney function by taking blood samples. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Начало: 23.03.2026 Край: 21.01.2028 Възраст: от 12 г. Treatment

Argentina, Australia, Belgium +26 Boehringer Ingelheim NCT07355296

1 … 3 4 5 6 7 … 154